Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson’s Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine
Condition(s):Parkinson’s DiseaseLast Updated:October 14, 2021Terminated
Hide Studies Not Open or Pending
Condition(s):Parkinson’s DiseaseLast Updated:October 14, 2021Terminated
Condition(s):Parkinson’s Disease Psychosis; Dementia With Lewy BodiesLast Updated:October 26, 2023Recruiting
Condition(s):Parkinson DiseaseLast Updated:May 12, 2023Recruiting
Condition(s):Neurodegenerative Diseases; Parkinson Disease; Parkinson Disease PsychosisLast Updated:February 28, 2024Recruiting
Condition(s):Schizophrenia; PsychosisLast Updated:May 3, 2021Withdrawn
Condition(s):Parkinson’s Disease PsychosisLast Updated:May 17, 2017Completed
Condition(s):Parkinson’s Disease PsychosisLast Updated:May 19, 2017Completed
Condition(s):SchizophreniaLast Updated:March 22, 2007Completed
Condition(s):Parkinson’s Disease; DyskinesiasLast Updated:July 2, 2017Completed
Condition(s):Hallucinations; Psychoses; Parkinson’s DiseaseLast Updated:December 7, 2005Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.